Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 2Thoracic 1Other hematologic neoplasm 1

Conditions

Pleural Effusion 1Lung Neoplasms 1

Interventions

Carboplatin 1174Cisplatin 891Pemetrexed 847pembrolizumab 626Paclitaxel 609Docetaxel 539Gemcitabine 428Radiotherapy 393Erlotinib Hydrochloride 381Nivolumab 344Bevacizumab 337Etoposide 297durvalumab 264Drug Therapy 260osimertinib 237atezolizumab 225Radiosurgery 196Gefitinib 186Vinorelbine 149Magnetic Resonance Spectroscopy 132Ipilimumab 129130-nm albumin-bound paclitaxel 125Cetuximab 113Blood Specimen Collection 106anlotinib 105tislelizumab 103Topotecan 103Specimen Handling 102Surgical Procedures, Operative 101Cyclophosphamide 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Tissue Plasminogen Activator × Thoracic × Clear all
NCT03678090 2020-03-05

The Safety and Efficacy of Fibrinolysis in Patients With an Indwelling Pleural Catheter for Multi-loculated Malignant Pleural Effusion.

Yale University

Phase 2 Withdrawn
Thoracic

Lung Neoplasms, Pleural Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡